Key facts
- Amferia’s last known valuation is $8.9M (Sep 2024).
- It has raised $7.9M; the latest was Later Stage VC ($3.5M) in Dec 2025.
- Notable investors include European Union, Almi Invest, Chalmers Ventures, Alexander Hars, British Corinthian Properties — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Amferia
- ·The full record, as it builds
Funding rounds
No funding rounds for Amferia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amferia
Developer of medical devices designed for the global antibiotic resistance crisis. The company develops and markets medical devices, emphasising antibacterial products that effectively kill bacteria when used in medical applications, such as wound care, enabling patients to prevent bacterial skin infections, including antibiotic-resistant infections, and for healthcare professionals to enhance infection control and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Molndal, Sweden
- Founded
- 2018
- Employees
- 10
- Website
- amferia.com/
- Ownership
- Privately Held (backing)
Amferia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amferia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amferia in its N-PORT filings yet. We sweep new filings monthly.